BridgeMD
New treatment option for Acute Decompensated Heart Failure
Official title EACH-ADHF: Early Comprehensive Rehabilitation in Patients With ADHF
ClinicalTrials.gov ID: NCT06161987
What this study is testing
- What it's testing
- EACH-ADHF: Early Comprehensive Rehabilitation in patients with ADHF study is a multi-center, parallel-group, randomized controlled trial designed to evaluate the effects of the early comprehensive rehabilitation including exercise and inspiratory muscle training, over a period of 6 weeks, on the quality of life of patients with ADHF.
- Time commitment: about 6 weeks
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age between 18-80
- At least one symptom of heart failure upon admission: Dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea or exertional fatigue.
- At least two of the signs of heart failure (HF): Distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, or...
- Able to independently perform basic activities of daily living before admission.
- Able to complete the baseline assessment and initiate the specified treatment.
You likely can't join if
- Acute heart failure caused by acute myocardial infarction.
- Severe aortic valve stenosis.
- Hemodynamic instability caused by poorly controlled arrhythmias.
- Severe heart failure and high-degree atrioventricular block, and inadequate heart rate response to pacing during exercise.
- Isolated pulmonary hypertension.
- Poorly controlled symptomatic orthostatic hypotension.
See the full eligibility criteria
- Age between 18-80
- At least one symptom of heart failure upon admission: Dyspnea at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea or exertional fatigue.
- At least two of the signs of heart failure (HF): Distended jugular veins, enlarged cardiac silhouette, apex beat displacement, third heart sound, or increased jugular venous pressure/central venous pressure/pulmonary...
- Able to independently perform basic activities of daily living before admission.
- Able to complete the baseline assessment and initiate the specified treatment.
- Able to walk 4 meters at the time of enrollment (assistive devices may be used).
- Agree to participate in this study, sign a written informed consent form, and is willing to cooperate with follow-up.
- Acute heart failure caused by acute myocardial infarction.
- Severe aortic valve stenosis.
- Hemodynamic instability caused by poorly controlled arrhythmias.
- Severe heart failure and high-degree atrioventricular block, and inadequate heart rate response to pacing during exercise.
- Isolated pulmonary hypertension.
- Poorly controlled symptomatic orthostatic hypotension.
- Hypertrophic obstructive cardiomyopathy.
- Stage 5 chronic kidney failure, defined as glomerular filtration rate \<15 ml/(min 1.73m²) or requiring dialysis.
- Undergoing screening tests with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than or equal to 5 times the upper limit of the normal range defined by the center.
- Awaiting a heart transplant or ventricular assist device implantation within six months, or having received a heart transplant.
- A history of chronic lung disease except for COPD, previous lung surgery, or diseases affecting lung function, such as scoliosis.
- Late-stage diseases other than heart failure.
- Any medical history that could potentially affect protocol compliance, such as severe mental disorders, severe cognitive impairment, substance abuse, or addiction.
- Severe language, psychological, or physical disabilities that prevent their participation in the program.
- Pregnant or lactating women, or those of childbearing potential who are unwilling or unable to use effective contraceptive measures.
- Involved in other treatment clinical trials.
- Patients deemed unfit for participation in this study by the researchers.
The study team makes the final eligibility decision.
Where it's taking place
- Guangzhou, Guangdong, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Guangzhou, Guangdong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.